Showing the single result

Betrixa 40

650.00৳ Strip
  • BetriXa prevents venous thromboembolism (VTE) in hospitalized adults with acute medical conditions.
  • Its active ingredient, betrixaban, selectively targets factor Xa to reduce thrombin generation.
  • Recommended initial dose followed by daily administration for 35 to 42 days.
  • Ensures comprehensive VTE prophylaxis for patients at risk.